| __timestamp | Blueprint Medicines Corporation | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 4326000 |
| Thursday, January 1, 2015 | 14456000 | 226206000 |
| Friday, January 1, 2016 | 19218000 | 94391000 |
| Sunday, January 1, 2017 | 27986000 | 53821000 |
| Monday, January 1, 2018 | 47928000 | 35463000 |
| Tuesday, January 1, 2019 | 96388000 | 46456000 |
| Wednesday, January 1, 2020 | 157743000 | 71318000 |
| Friday, January 1, 2021 | 195293000 | 135256000 |
| Saturday, January 1, 2022 | 237374000 | 102708000 |
| Sunday, January 1, 2023 | 295141000 | 129620000 |
| Monday, January 1, 2024 | 359272000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and ImmunityBio, Inc. over the past decade. From 2014 to 2023, Blueprint Medicines has seen a staggering increase in SG&A expenses, growing by approximately 3,640%, from $7.89 million to nearly $295 million. In contrast, ImmunityBio's expenses have fluctuated, peaking in 2015 at $226 million before stabilizing around $130 million in 2023. This trend highlights Blueprint's aggressive expansion strategy, while ImmunityBio appears to be optimizing its operational costs. As these companies continue to innovate, their financial strategies will play a pivotal role in shaping their market positions.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Research and Development: Comparing Key Metrics for Blueprint Medicines Corporation and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Ionis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ImmunityBio, Inc.
Breaking Down SG&A Expenses: Bausch Health Companies Inc. vs ImmunityBio, Inc.